NEW YORK, NY--(Marketwired - May 13, 2014) -
Celmatix, a privately held precision medicine company focused on maximizing lifelong fertility, today announced the initiation of a clinical trial for Polaris, the world's first data fusion platform that helps doctors at fertility clinics design personalized treatment plans tailored to a couple's specific clinical metrics. The predictive models that power Polaris are the first to calculate the cumulative probability across various treatment types and multiple treatment cycles. Polaris is also the first platform that shows side-by-side comparisons of a patient's cumulative chances for success with in-vitro fertilization (IVF) now and in the future, timed intercourse, and non-IVF treatments.
The 12-month randomized prospective clinical study will enroll 1,000 patients at clinics across the country, including Reproductive Medicine Associates of New York, Reproductive Medicine Associates of New Jersey, Reproductive Medicine Associates of Texas, Reproductive Medicine Associates of Philadelphia, Washington University at St. Louis, and the Center for Advanced Reproductive Services at The University of Connecticut. Using an independent validation set, the models that power Polaris have been shown to be more accurate than any published predictive models on fertility treatment outcomes. The goal of the trial will be to confirm the clinical utility of Polaris in a prospective study.
Dr. Piraye Yurttas Beim, Founder and CEO, of Celmatix, said, "When couples are having trouble conceiving, it can be a confusing and emotionally stressful time. Polaris helps doctors harness data and biology to design and communicate personalized treatment plans that ultimately help patients reach successful outcomes more efficiently. Today, a woman is counseled on her chances of conceiving with or without treatment largely based on age. However, these averages can underestimate a woman's chances for success because there are so many factors that contribute to a woman's ability to get or stay pregnant. What makes Polaris unique is that it is the first platform to calculate a woman's cumulative chances of success across different treatment types using all of the factors that have been statistically shown to be the most predictive, including age, hormone levels, and other biological metrics. In short, Polaris is helping bring personalized medicine to the millions of women in the US who have difficulty getting or staying pregnant each year."
Dr. Alan Copperman, Director of Infertility and Vice Chairman of Obstetrics and Gynecology at Mount Sinai Medical Center, is Co-Founder & Co-Director of Reproductive Medicine Associates of New York, a leading New York City-based fertility clinic and one of the first test sites for the clinical trial. Dr. Copperman said, "Polaris has the potential to bring greater clarity to a difficult and emotional process. Celmatix's human-centered approach to helping women maximize their fertility potential is innovative and we look forward to unlocking Polaris's potential during the course of the year-long clinical trial."
About Celmatix, Inc.
Founded in 2009, Celmatix is a New York City-based precision medicine company focused on maximizing lifelong fertility. By leveraging innovations in biology, data science, and technology, Celmatix is creating products that help personalize the treatment for infertility and fertility planning. Celmatix's key research discoveries include powerful predictive models that can calculate personalized chances for success for different treatment options across multiple cycles and the identification of Fertilome™DNA, the regions of the human genome that are most likely to influence a woman's fertility potential. For more information, visit www.celmatix.com.